Refine by
Metabolism Disease Articles & Analysis: Older
70 news found
These models have been specifically designed to enable research on different types of diabetes including type 1, type 2, and gestational diabetes, providing valuable insights into disease mechanisms and potential treatment options. Diabetes mellitus is a chronic, systemic, metabolic disease caused by the long-term combination of genetic factors ...
Ace Therapeutics is a preclinical contract research provider engaged in metabolic disorders, infectious diseases and parasites, neurological disorders, ophthalmic diseases, gastrointestinal disorders, and immune system diseases. ...
Ace Therapeutics is a preclinical contract research provider engaged in metabolic disorders, infectious diseases and parasites, neurological disorders, ophthalmic diseases, gastrointestinal disorders, and immune system diseases. ...
Insights into this paradigm are expected to link the regulation of pathways to the restoration of immune homeostasis for the treatment of a wide range of diseases, including infectious diseases, autoimmune disorders, allograft rejection and malignancies. To help scientists better understand the regulation and role of mTOR in metabolic regulation ...
In contrast to T2D, which is primarily a chronic metabolic disease, in type 1 diabetes the insulin secreting cells of the pancreas are destroyed, which is deemed to be attributable to factors such as genetics and environmental triggers. ...
ByBayer AG
HLA regions are associated with the greatest number of human diseases in the human genome, and HLA typing is particularly important for assessing immune compatibility between organ donor and recipient pairs. There are more than 100 kinds of diseases related to HLA, involving autoimmune diseases, immunodeficiency diseases, ...
Dr. Ali Tinazli's post at the Forbes magazine about "History Of Health Technologies And Meaningful Change In The Era Of Health 4.0" The medicine in ancient Egypt is some of the oldest in history. Although rudimentary, it was already highly personalized and with exclusive access. During the Renaissance—one of the most remarkable ages of humankind—medicine ...
It comprises of pluripotent stem cell-derived dopaminergic neurons that are implanted into the brain, thus taking target at the root cause of the disease. According to the Parkinson’s Foundation, more than 10 million people worldwide suffer from Parkinson’s disease. ...
ByBayer AG
“We are excited to combine these unique platforms to develop next-generation genetic therapies with the potential to transform the lives of patients suffering from a wide range of debilitating genetic diseases.” In June 2022, ReCode announced the closing of a $200 million Series B extension financing round, co-led by Leaps by Bayer, the impact investment unit of ...
ByBayer AG
LB-P8 is, to the best of company's knowledge, the first drug to be granted orphan drug designation in the field of microbiome-based treatment for metabolic diseases. The US FDA's ODD program supports the development of treatments for rare diseases with high unmet medical needs and provides various incentives. ...
BioPharma: Microbiome therapeutics, anti-microbial resistance, personalised/stratified medicine, therapeutics for gastrointestinal and infectious diseases, immuno-oncology/autoimmune disease and metabolic health. Anthony Finbow, CEO, Eagle Genomics, said: “We are the pre-eminent platform business using next-generation graph technology and ...
Findings also support this novel approach for extending the delivery of gene replacement strategies to target metabolic diseases amenable to HSCT. The data from treated subjects demonstrate that intravenous FBX-101 after HSCT infusion has been safe and well tolerated. ...
Target knockdown and safety results support continued clinical development Alnylam and Regeneron intend to initiate a Phase 2 study in late 2022 Detailed results to be presented at an upcoming medical congress CAMBRIDGE, Mass. & TARRYTOWN, N.Y.--(BUSINESS WIRE)--Sep. 15, 2022-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Regeneron Pharmaceuticals (Nasdaq: REGN) announced today ...
Leveraging Lifespin’s Comprehensive Metabolic Database Lifespin has built one of the largest and most comprehensive databases of metabolic health profiles across healthy and diseased individuals covering multiple age and gender groups as well as specific diseases in neurology, oncology, and inflammation. ...
The results of this study may represent another advancement in the management of this disease, and we now look forward to the further analysis of secondary ...
Clinical data support preclinical observations that this approach may lessen many of the immune challenges previously observed with systemic AAV gene delivery and can create a novel approach for extending the delivery of gene replacement strategies to target metabolic diseases amenable to UCBT. The first patient’s data from the RESKUE clinical trial ...
(NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced the winners of its 2017 weight loss contest, which recognizes patients for their successful weight loss with the ReShape Balloon™. ...
New Calibration Tubes, in Three Sizes, Will Simplify Gastric and Bariatric Procedures Including Laparoscopic Sleeve Gastrectomy, Gastric Bypass and Gastric Banding Company to Introduce Product at IFSO 2022 World Congress in August; Sales to Commence in September ReShape Lifesciences (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions ...
ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that its Board of Directors has appointed Paul F. ...
Ariana Pharma, the leading eXplainable Artificial Intelligence (xAI) drug development company, announce the appointments of Dr. Marion Soto as Vice President, Business Development and Bertrand Lellouche as Chief Financial Officer. The financial and commercial experience of Marion and Bertrand will further drive Ariana’s accelerated growth. Marion and Bertrand will be bringing their ...